Abstract SAT0461 - Table 1. 
SAT0462 SECUKINUMAB PROVIDES SUSTAINED PASDAS RELATED LOW DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: 2 YEAR RESULTS FROM THE FUTURE 2 STUDY
2 Here, we report the ability of secukinumab to reach and sustain PASDAS based low disease activity (LDA) up to 104 wks in the FUTURE 2 study using a post-hoc exploratory analysis. Methods: 397 patients (pts) with active PsA were randomised to subcutaneous (s.c.) secukinumab (300mg, 150mg, or 75mg) or placebo (PBO) at baseline (BL), Wks 1, 2, and 3, and every 4 wks (q4w) from Wk 4. PBO nonresponder and responder pts were re-randomised to secukinumab 300 or 150mg s.c. q4w from Wk 16 and 24, respectively. PASDAS is derived from physician's global VAS, patient's global VAS, SF-36 PCS, tender and swollen joints (TJC 68 and SJC 66), Leeds enthesitis count, dactylitis count and CRP level and has cut-points for high disease activity (HDA≥5.4), low disease activity (LDA<3.2) and remission (REM≤1.9).
3 PASDAS was assessed in the overall population and in pts stratified by prior anti-TNF use (naïve/inadequate response [IR] ) and disease duration (≤2 years vs. >2 years since diagnosis) and reported using non-mutually exclusive categories at group level and as observed analysis. Secukinumab 75mg data are not reported as this was not considered an effective dose. Conclusions: A higher proportion of secukinumab-treated pts at Wk 16 achieved PASDAS LDA than PBO, with LDA sustained at group level at Wk 104. Discriminatory effect of PASDAS was consistent with that previously reported in the GRACE project.
4 A higher proportion of anti-TNFα-naïve pts treated with secukinumab achieved and sustained PASDAS LDA than anti-TNFα-IR pts whereas similar proportion of pts treated with secukinumab achieved PASDAS LDA irrespective of time since diagnosis (≤2 years vs. >2 years). Background: Fatigue, a common symptom in patients (pts) with PsA, can negatively impact HRQoL and social functioning. Secukinumab (SEC), a fully human anti-IL-17A mAb, rapidly improved signs and symptoms, physical functioning, HRQoL, and fatigue in pts with PsA.
1,2
Objectives: To assess the long-term effects of SEC on fatigue in TNF inhibitor (TNF)-naïve PsA pts and those with an inadequate response or intolerance to TNF inhibitor therapy (TNF-IR). Methods: 606 and 397 pts were randomized to SEC or placebo (PBO) in FUTURE 1 (10 mg/kg IV followed by 150 or 75 mg SC) and FUTURE 2 (300, 150, or 75 mg SC), respectively. At Wk 16, PBO pts with ≤20% reduction in tender/swollen joint count (non-responders) were re-randomized to SEC 150 or 75 mg SC (FUTURE 1) and SEC 300 or 150 mg SC (FUTURE 2); responders were re-randomized at Wk 24. Pts in FUTURE 1 could enter a LTE study at Wk 104 (NCT01892436). Across both studies, approximately 68% of pts were TNF-naïve and 32% were TNF-IR. Fatigue was assessed at baseline (BL) and Wks 4, 8, 12, 16, 24, 52, 104 , and 156 (FUTURE 1 only) using FACIT-F (higher scores = less fatigue). Fatigue response was defined by an increase in FACIT-F score of ≥4 from BL (corresponding to the MCID). Correlations between BL characteristics and improvements in fatigue were investigated using a logistical regression model. Only data with approved doses of SEC (300/150 mg) are shown. Results: at BL across groups in FUTURE 1 and 2, respectively. Improvements in fatigue seen with all doses of SEC vs. PBO from Wks 4-24 were sustained through 156 wks in FUTURE 1 and 104 wks in FUTURE 2 in both the overall population and subgroups stratified by prior exposure to TNF (Table) . The numerically higher responses with SEC 150 vs. 300 mg in this observed analysis were as a result of a higher rate of discontinuation due to lack of efficacy with the lower dose, which inflated the response rate. In the overall population, the LS mean change (±SEM) from BL in FACIT-F was significantly greater with SEC vs. PBO 
